Paul Weiss, Kirkland Steer $10.9B AbbVie, Apogee Deal
law360
5 days ago
6 views
AbbVie said Monday it has agreed to buy Apogee Therapeutics, a company developing therapies for inflammatory and immunological diseases, at a total equity value of approximately $10.9 billion, with Paul Weiss Rifkind Wharton & Garrison LLP and Kirkland & Ellis LLP advising.
Continue Reading
Sign up for FREE to read the full article and access 129K+ alternative investment headlines.